Summary:
Enveda Biosciences uses AI to expedite the process of discovering new medicines from nature.
Enveda's AI analyzes a vast database of medicinal plants and their uses across cultures, identifying plants with the highest potential for medical applications.
Two of Enveda's drugs are expected to begin clinical trials this year, one for treating skin conditions like eczema and the other for inflammatory bowel diseases.
Enveda has raised $55 million in Series B2 funding, demonstrating the strong interest in its AI-powered approach to drug discovery.
Enveda Biosciences, a Colorado-based biotech company, is using AI to speed up the process of discovering new medicines from nature. Inspired by the fact that an estimated 40% of modern pharmaceutical products have roots in traditional remedies, Enveda's AI analyzes a vast database of medicinal plants and their uses across cultures.
The company's database currently lists 38,000 medicinal plants linked to approximately 12,000 diseases and symptoms. Enveda's AI identifies plants with the highest potential for medical applications, and its team then gathers materials and tests them using the company's lab and AI model. This approach, which analyzes the entire sample rather than focusing on individual molecules, has already yielded promising results.
Two of Enveda's drugs are expected to begin clinical trials this year, one for treating skin conditions like eczema and the other for inflammatory bowel diseases. Enveda's scientific progress has also attracted significant investment, with the company recently raising $55 million in Series B2 funding. This funding will fuel further research and development as Enveda continues to explore the vast potential of nature for drug discovery.
Comments